ABSTRACT
INTRODUCTION Within the last fi ve years, the focus of treatment for agerelated macular degeneration (AMD)-related choroidal neovascularization (CNV) has been dominated by drugbased approaches, and anti-VEGF therapy has prevailed as the most effective treatment thus far. However, pharmacologic therapies so far have had certain limitations and drawbacks, with the burden of repeat treatment at the top of the list, and there are patients who are refractory to anti-VEGF therapy. Consequently, alternative treatment modalities are still being explored and utilized, especially as part of a combination therapy approach. One such technique, called feeder vessel treatment (FVT), specifi cally targets the blood vessels supplying the CNV. FVT, which was introduced years ago and remains in limited use today, is an attractive approach because, unlike pharmacologic interventions, the treatment is directed and defi nitive. The effect of the treatment in theory should not diminish with time.
